• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: M&A deal-making in 2016 weaker than 2015

Report: M&A deal-making in 2016 weaker than 2015

October 6, 2016
CenterWatch Staff

Mergermarket's Q3 trend report shows that global M&A deal-making in 2016 has not been able to achieve the same record heights reached last year, with political uncertainty, increased regulation and decreased confidence all weighing down activity.

To-date in 2016, 12,283 deals worth $ 2.2 trillion represents a 20.2% value decrease compared to the same period in 2015. Despite this, M&A deal value has experienced two quarterly value increases this year, with Q3 ($812.9 billion) increasing 8.8% compared to Q2 ($747.2 billion).

Key highlights from the report include:

  • Industrials & Chemicals was the most targeted sector globally with 2,313 deals worth US$ 416.8 billion representing a 41.1% value increase compared to the same period in 2015.
  • Acquisitive Chinese buyers invest in 201 deals worth $141.2 billion so far this year targeting firms outside of the Asia-Pacific region, overtaking all annual deal values and volumes on Mergermarket record (since 2001).
  • Opportunistic dealmakers engage in bargain hunt for U.K. assets following Brexit vote, with inbound activity jumping 283.0% by value compared to Q2.

Bayer's bid for Monsanto company was the largest deal in Q3, worth $65.3 billion and boosting deal value for the Industrials and Chemicals sector.

Goldman Sachs leads the advisor rankings, having advised on 185 deals worth $602.2 billion.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing